Vanda shareholders re-elect three Class II directors and approve equity plan amendment

Vanda Pharmaceuticals Inc.

Directors Dugan, Duncan, and Ward re-elected with majority support; broker non-votes of ~10M shares.
Shareholders ratified PwC as auditor for FY 2026 with 48.1M votes for.
Advisory say-on-pay passed; ~35.2M for, ~3.2M against.
Amendment to 2016 Equity Plan to increase authorized shares approved with 31.7M for, 6.7M against.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Vanda Pharmaceuticals Inc. shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The Company’s stockholders ratified the selection, by the Audit Committee of the Board, of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Vanda Pharmaceuticals Inc. shareholders approved Advisory vote on named executive officer compensation at the 2026-06-04 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The Company’s stockholders approved on an advisory, non-binding basis the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Vanda Pharmaceuticals Inc. shareholders approved Election of three directors to serve as Class II directors for a term of three years until the Company's 2029 annual meeting of stockholders at the 2026-06-04 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The Company’s stockholders elected the following directors to serve as Class II directors until the Company’s 2029 annual meeting of stockholders.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Vanda Pharmaceuticals Inc. shareholders approved Amendment to Company's Amended and Restated 2016 Equity Incentive Plan to increase aggregate number of shares authorized for issuance at the 2026-06-04 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The Company’s stockholders approved an amendment to the 2016 Plan to increase the aggregate number of shares authorized for issuance under the 2016 Plan.

View on SEC.gov

404 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-041298

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.